Physician profile
Ali Baghian
NPI 1083935878
$6,724.03
in general payments reported to CMS, 2019-2025
54 companies · $32.97 in 2025
The $32.97 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $1,604 · 2021: $2,244 · 2022: $2,153 · 2023: $273 · 2024: $167 · 2025: $32.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274 · Long Term Medical Supply Or Device Loan: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.68 |
| Long Term Medical Supply Or Device Loan | $199.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,263.84 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $418.41 | 2020-2023 | Imbruvica |
| Incyte Corporation | $416.25 | 2019-2022 | |
| Pfizer INC. | $332.21 | 2019-2022 | |
| Eisai INC. | $327.29 | 2020-2023 | |
| Astellas Pharma US INC | $317.03 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $312.06 | 2020-2022 | |
| Celgene Corporation | $236.39 | 2019-2022 | |
| Amgen INC. | $234.39 | 2020-2022 | |
| Janssen Biotech, INC. | $217.96 | 2020-2022 | |
| Seagen INC. | $143.62 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $143.39 | 2020-2022 | |
| Daiichi Sankyo INC. | $138.46 | 2019-2022 | |
| Foundation Medicine, INC. | $134.96 | 2019-2020 | |
| Springworks Therapeutics, INC. | $122.11 | 2024 | Ogsiveo |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Baghian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.